Literature DB >> 1661708

Effect of an immunomodulating agent, RU 414740, on polymorphonuclear responsiveness after burn injury.

M Roch-Arveiller1, J Fontagne, A el Abbouyi, D Raichvarg, J P Giroud.   

Abstract

An impairment of polymorphonuclear leukocyte (PMN) functions has been described following burn trauma. It was thus of interest to investigate the effect of RU 41740, an agent known to stimulate these cells, on rat PMN functions after burn injury. In the present study the responsiveness to classical stimuli of PMN from untreated burned rats was approximately 40% lower than healthy control values. In vitro treatment with RU 41740 increased oxidative metabolism of PMNs from burned and healthy rats. The effect was dose-related but was most striking in the case of PMNs from healthy rats. Significant differences were obtained with concentrations higher than 1 micrograms/ml for healthy rats but only 10 micrograms/ml for burned rats. In vivo treatment with RU 41740 also led to an enhancement of PMN oxidative metabolism on both burned and healthy rats. The maximal effective dose was 10 mg/kg/day in both cases. In contrast, 25 and 50 mg/kg/day doses inhibited PMN oxidative metabolism.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1661708     DOI: 10.1007/bf00923341

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  36 in total

1.  [Repeated sampling of rat polymorphonuclear leucocytes from the pleural cavity. Application for the study of leucocyte chemotaxis (author's transl)].

Authors:  J P Giroud; M Roch-Arveiller; O Muntaner
Journal:  Nouv Rev Fr Hematol       Date:  1978

2.  A standard animal burn.

Authors:  H L Walker; A D Mason
Journal:  J Trauma       Date:  1968-11

3.  Drug activity "in vitro" and "in vivo" on leucocyte chemotaxis.

Authors:  M Roch-Arveiller; D Pham-Huy; O Muntaner; L Maman; J P Giroud
Journal:  Biomed Pharmacother       Date:  1987       Impact factor: 6.529

Review 4.  Active oxygen species and the functions of phagocytic leukocytes.

Authors:  J A Badwey; M L Karnovsky
Journal:  Annu Rev Biochem       Date:  1980       Impact factor: 23.643

5.  [Double-blind study of an immunomodulator of bacterial origin (Biostim) in the prevention of infectious episodes in chronic bronchitis].

Authors:  J R Viallat; D Costantini; C Boutin; P Farisse
Journal:  Poumon Coeur       Date:  1983 Jan-Feb

6.  Human tumor necrosis factor is a potent activator of the oxidative metabolism in human polymorphonuclear neutrophilic granulocytes: comparison with human lymphotoxin.

Authors:  A Kapp; G Zeck-Kapp; D Blohm
Journal:  J Invest Dermatol       Date:  1989-03       Impact factor: 8.551

7.  Effect of cytokines on polymorphonuclear neutrophil infiltration in the mouse. Prostaglandin- and leukotriene-independent induction of infiltration by IL-1 and tumor necrosis factor.

Authors:  T J Sayers; T A Wiltrout; C A Bull; A C Denn; A M Pilaro; B Lokesh
Journal:  J Immunol       Date:  1988-09-01       Impact factor: 5.422

8.  Mechanisms of loss of human neutrophil chemotaxis following thermal injury.

Authors:  R D Nelson; S R Hasslen; D H Ahrenholz; L D Solem
Journal:  J Burn Care Rehabil       Date:  1987 Nov-Dec

9.  Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline.

Authors:  G W Sullivan; H T Carper; W J Novick; G L Mandell
Journal:  Infect Immun       Date:  1988-07       Impact factor: 3.441

10.  Synthetic immunomodulators for prevention of fatal infections in a burned guinea pig model.

Authors:  J D Stinnett; L D Loose; P Miskell; C L Tenney; S J Gonce; J W Alexander
Journal:  Ann Surg       Date:  1983-07       Impact factor: 12.969

View more
  1 in total

1.  Effects of niflumic acid on polyphosphoinositide and oxidative metabolism in polymorphonuclear leukocytes from healthy and thermally injured rats.

Authors:  M Tissot; M Roch-Arveiller; J Fontagne; J P Giroud
Journal:  Inflammation       Date:  1992-12       Impact factor: 4.092

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.